News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Yakult Honsha, Terumo To Co-develop Liposomal Formulation Of Irinotecan
May 22, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Tokyo, May 19, 2006 (JCN) - Yakult Honsha announced on May 18 that it will develop a liposomal formulation of irinotecan, a kind of anticancer agent, with Terumo. A development code for the agent is IHL-305.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Asia
MORE ON THIS TOPIC
Executive appointments
Merck Reorganizes Human Health Work Into Two New Units
February 23, 2026
·
1 min read
·
Annalee Armstrong
Weight loss
Novo’s CagriSema Falls to Lilly’s Zepbound in Daring Head-to-Head Test
February 23, 2026
·
4 min read
·
Annalee Armstrong
Layoff Tracker
BMS, Catalent Further Whittle Workforces
February 23, 2026
·
57 min read
·
BioSpace Editorial Staff
Insights
Redefining Obesity Treatment Beyond GLP-1 Limits
February 19, 2026
·
1 min read
·
Jennifer Smith-Parker
